A prospective multicenter study for characterization of renal function G1b CHC patients with CKD-3 treated with elbasvir plus grazoprevir

A prospective multicenter study for characterization of renal function G1b CHC patients with CKD-3 treated with elbasvir plus grazoprevir - Elbasvir plus grazoprevir treatment for patients with G1b CHC patients with CKD-3

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026542

Enrollment

Registered

2017-03-14

Start date

2017-03-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genotype 1b chrinic hepatitis C patients with CKD-3

Interventions

Treatment of elbasvir plus grazoprevir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who are infected with HCV genotype 1b 2.Patients with moderate chronic kidney disease (CKD stage 3)

Exclusion criteria

Exclusion criteria: 1.Decompensated liver cirrhosis (Child Pugh B/C) 2.Patients with co-infection with HBV or HIV 3.Patients who are pregnant females, or females who may become pregnant 4.Patients who are under medication with drugs listed as contraindication in a package insert 5.Patients judged to be inappropriate as subjects for the study

Design outcomes

Primary

Measure	Time frame
The rate of sustained viral response.	—

Secondary

Measure	Time frame
(1)Transition of renal function (2)Safety(the rate of discontinuation) (3)Biochemical efficacy	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026